2
Announcements
Trials
Browse
Landscape
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Breast
1
Conditions
Cardiovascular Diseases
3
Breast Neoplasms
3
Metabolic Syndrome
2
Stomach Neoplasms
1
Sarcoidosis
1
Rectal Neoplasms
1
Obesity
1
Non-alcoholic Fatty Liver Disease
1
Lymphoma, Large B-Cell, Diffuse
1
Lung Neoplasms
1
Lung Diseases, Interstitial
1
Liver Cirrhosis
1
Hodgkin Disease
1
Fatigue
1
Colorectal Neoplasms
1
Cardiotoxicity
1
Breast Diseases
1
Interventions
Anastrozole
8
exemestane
7
Trastuzumab
7
Letrozole
7
palbociclib
6
Docetaxel
6
abemaciclib
5
Fulvestrant
5
ribociclib
4
pyrotinib
4
entinostat
4
Cyclophosphamide
4
Tamoxifen
3
Doxorubicin
3
pertuzumab
2
Sodium Chloride
2
Paclitaxel
2
Lapatinib
2
Gonadotropin-Releasing Hormone
2
Exercise
2
Everolimus
2
Epirubicin
2
Drug Evaluation
2
Capecitabine
2
Botulinum Toxins, Type A
2
Blood Specimen Collection
2
Aromatase Inhibitors
2
AZD9833
2
tucatinib
1
trastuzumab deruxtecan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Breast Diseases
×
Blood Pressure
×
Clear all
NCT05006196
2026-05-20
IMOGEN
Perspectum
Active not recruiting
1,030 enrolled